Research on the Physiological Characteristics of the Gastrointestinal Tract in Chinese Volunteers
NCT ID: NCT04743726
Last Updated: 2021-02-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
24 participants
OBSERVATIONAL
2020-10-31
2022-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Contrast-enhanced Multispectral Optoacoustic Tomography for Functional Assessment of the Gastrointestinal Transit
NCT05933096
Correlation of Somatic Dysfunction With Gastrointestinal Endoscopic Findings
NCT01394198
Gastrointestinal Transit Times and Motility in Healthy Volunteers Obtained by Motilis-3D-transit
NCT01635491
Mucosal Microbiome in Human Gastric Intestinal Metaplasia and Duodenal Tissue.
NCT02428426
Clinical Study of Intestinal Barrier Dysfunction After Gastrointestinal Surgery
NCT06596070
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Endoscopy
Chinese volunteers who are scheduling for gastro-colonoscopy
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Volunteers who have a full understanding of the content, process and possible adverse reactions of the study and have signed an informed consent form before the clinical trial;
3. Volunteers who are able to complete the clinical trial according to the protocol;
4. Male and female volunteers between the ages of 18 and 60 (including both ends) on the date of signing the consent form;
5. Female volunteers are non-pregnant or non-lactating women, and will live asexually after enrollment until the end of the trial;
6. Male volunteers weigh no less than 50 kg, female volunteers weigh no less than 45 kg, and the body mass index (BMI) of male and female volunteers within the range of 19.0-26.0 kg/m2 (including cut-off values);
7. The comprehensive physical examination, routine laboratory examinations are normal or abnormal, but the investigator judges that there is no clinical significance;
8. Volunteers who are able to abstain from alcohol, coffee, non-prescription drugs or prescription drugs, and no food and beverages related to grapefruit within 14 days before the start of the test until the end of the test;
9. Volunteers have no history of smoking
Exclusion Criteria
2. Volunteers who do not comply with the relevant regulations about endoscope;
3. Volunteers with endoscope contraindications;
4. Volunteers with HCV, HIV, HBsAg and/or syphilis positive antibody;
5. Volunteers with allergic physique;
6. Volunteers with needlesickness, blood phobia, difficult in collecting blood and in tolerating local anesthesia;
7. Females who are pregnant, breastfeeding, or taking birth control pills for less than 3 months;
8. Volunteers have bleeding disorders, or therapeutic anticoagulation (warfarin, aspirin, clopidogrel, traditional Chinese medicine, etc.), or anesthesia dependence or alcohol dependence;
9. Volunteers have the smoking history, alcoholism history, alcohol screening positive, drug screening positive, history of drug abuse in the past five years or administration drugs in the three months prior to the trial;
10. Alcoholics (14 units of alcohol consumed per week: 1 unit = 285 mL beer, or 25 mL spirits, or 100 mL wine) and volunteers who cannot prohibition from the time of enrollment to the end of the study;
11. Volunteers who have a history of gastrointestinal disease with a definite severity or have diseases that have been considered unsuitable for participating in this study by researchers;
12. Volunteers with obvious gastrointestinal discomfort within 6 months before the start of the clinical trial;
13. Volunteers who have undergone gastrointestinal and liver surgery and those who have received any other surgery 6 months before the clinical trial;
14. The clinical laboratory examination is abnormal and the researchers judges that it has clinical significance;
15. Volunteers who have taken any clinical trial drugs within 3 months;
16. Volunteers who have used any antibiotics within 3 months;
17. Volunteers who have used any drug within 1 month;
18. Volunteers with hypertension (systolic blood pressure\>139 mmHg,diastolic blood pressure\>89 mmHg);
19. Volunteers with Parkinson's disease or family history of Parkinson's disease;
20. Volunteers with a family history of sudden cardiac death or arrhythmia;
21. Habitual drink, including coffee, tea, grapefruit juice and so on;
22. Significant weight loss recently;
23. Researcher judge that the volunteer has other factors that are not suitable for participating in this study, regardless of their severity
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dongyang Liu
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dongyang Liu
Vice director of Drug Clinical Trial Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dongyang Liu
Role: PRINCIPAL_INVESTIGATOR
Drug Clinical Trial Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dongyang Liu
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Van Den Abeele J, Rubbens J, Brouwers J, Augustijns P. The dynamic gastric environment and its impact on drug and formulation behaviour. Eur J Pharm Sci. 2017 Jan 1;96:207-231. doi: 10.1016/j.ejps.2016.08.060. Epub 2016 Sep 3.
Hayashi M, Matsumoto N, Takenoshita-Nakaya S, Takeba Y, Watanabe M, Kumai T, Takagi M, Tanaka M, Otsubo T, Kobayashi S. Individual metabolic capacity evaluation of cytochrome P450 2C19 by protein and activity in the small intestinal mucosa of Japanese pancreatoduodenectomy patients. Biol Pharm Bull. 2011;34(1):71-6. doi: 10.1248/bpb.34.71.
Berggren S, Gall C, Wollnitz N, Ekelund M, Karlbom U, Hoogstraate J, Schrenk D, Lennernas H. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol Pharm. 2007 Mar-Apr;4(2):252-7. doi: 10.1021/mp0600687. Epub 2007 Jan 31.
Kalantzi L, Goumas K, Kalioras V, Abrahamsson B, Dressman JB, Reppas C. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies. Pharm Res. 2006 Jan;23(1):165-76. doi: 10.1007/s11095-005-8476-1. Epub 2006 Dec 1.
Perez de la Cruz Moreno M, Oth M, Deferme S, Lammert F, Tack J, Dressman J, Augustijns P. Characterization of fasted-state human intestinal fluids collected from duodenum and jejunum. J Pharm Pharmacol. 2006 Aug;58(8):1079-89. doi: 10.1211/jpp.58.8.0009.
Vasapolli R, Schutte K, Schulz C, Vital M, Schomburg D, Pieper DH, Vilchez-Vargas R, Malfertheiner P. Analysis of Transcriptionally Active Bacteria Throughout the Gastrointestinal Tract of Healthy Individuals. Gastroenterology. 2019 Oct;157(4):1081-1092.e3. doi: 10.1053/j.gastro.2019.05.068. Epub 2019 Jun 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CPPO-PKMS-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.